Kymera Therapeutics, Inc. (KYMR) shares fell 4.8% to $106.68 as of October 14, 2026, a moderate decline from the prior close of $112.08. BestStocks flagged the session as a major change for KYMR. The move is tied to company news. Below, we break down what changed for KYMR, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Company News
KYMR fell 4.8% in its latest session, moving from $112.08 to $106.68.
NewsLow confidence
Rel. volume
0.9×
Below Avg
Vs peers
—
No comparable peers
Market cap
$8.8B
NASDAQ Global Market
Analyst target
$138
+29.5% vs price
Price chart
Sep 14 – Oct 14
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Kymera Therapeutics, Inc. investors
For Kymera Therapeutics, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum. Weighing against that: Material negative event; Negative session, down 4.8%. Wall Street's consensus price target sits at $138.20, implying +29.5% upside from $106.68. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (57/100). With earnings roughly 20 days out, the next report is the most likely near-term test of the move.
KYMR price reaction
KYMR last traded at $106.68, down $5.40 (-4.82%) from the previous close of $112.08. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $105.98 and $122.06, and it currently sits about 4% of the way up that band.
Bullish and bearish analyst opinions on Kymera Therapeutics, Inc. (KYMR)
The consensus analyst price target on Kymera Therapeutics, Inc. (KYMR) is $138.20, 29.5% above the recent $106.68. Over the past 90 days analysts logged 1 upgrade, 8 maintains, and 0 downgrades. Here is how the bullish and bearish cases on KYMR line up.
▲ The bullish case
+Wall Street's consensus price target of $138.20 implies +29.5% upside from $106.68.
+The Street's most bullish target is $180.00 (+68.7%).
+1 analyst upgrade in the past 90 days, most recently Wolfe Research to Outperform (2026-09-10).
+Positive price momentum.
▼ The bearish case
−The most bearish analyst target is $97.00 (-9.1%).
−Material negative event.
−Negative session, down 4.8%.
−Kymera Therapeutics, Inc. (KYMR) moved −7.50% from $119.35 to $110.40 on 2026-07-13.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 14, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Kymera Therapeutics, Inc. (KYMR) moved −3.74% from $110.83 to $106.68 on 2026-10-13 after law firm Purcell & Lefkowitz announced an initiation of a shareholder investigation into potential fiduciary duty breaches by KYMR directors.
Material / Earnings2026-10-09+2.8%
Kymera Therapeutics (KYMR) moved +2.61% from $109.54 to $112.40 on 2026-10-09. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.4x the 5-day average, suggesting modest institutional interest, but the move appears to be driven by technical factors rather than a discrete catalyst.
Material / Earnings2026-10-08+0.9%
Kymera Therapeutics, Inc. (KYMR) moved +2.51% from $106.62 to $109.30 on 2026-10-08. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 1.1x, indicating the move was not driven by unusual trading activity.
Material / Earnings2026-10-07+2.2%
Kymera Therapeutics, Inc. (KYMR) moved +3.60% from $104.58 to $108.35 on 2026-10-07. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Material / Earnings2026-10-06-3.5%
Kymera Therapeutics, Inc. (KYMR) moved -4.55% from $111.03 to $105.98 on 2026-10-06. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move appears to be driven by technical factors: KYMR reached a new 30-day low, though volume remained near its 5-day average.
Kymera Therapeutics fell 2.98% to $106.84, driven by a combination of insider profit-taking and broad profit-taking after a year-long rally exceeding 100%. CEO Nello Mainolfi sold 30,000 shares (~$3.41M) on October 1 under a Rule 10b5-1 trading plan, which typically triggers short-term negative sentiment. Volume remained below average at 0.68x expected for this point in the session.
News2026-09-30+1.2%
Kuehn Law initiates shareholder investigation into KYMR officers and directors for potential fiduciary duty breaches.
Kymera Therapeutics, Inc. moved -2.94% intraday from $115.81 to $112.41. Cited by Google's AI Overview as a source for KYMR's move on 2026-09-25 (investors.kymeratx.com).
Upcoming catalysts & outlook
Next earnings
2026-11-03 (est.)
in 20 days
10-Q Filing (est.)
2026-11-04
Medium impact
Thesis shift
Bearish Shift
bearish signal
Risk level
Medium
from change events
Frequently asked questions about KYMR
Why did Kymera Therapeutics, Inc. (KYMR) stock move?
KYMR fell 4.8% to $106.68. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did KYMR stock fall?
KYMR lost 4.82% ($5.40) versus the prior close of $112.08, last trading at $106.68 on 0.9× average volume.
When is Kymera Therapeutics, Inc.'s next earnings date?
KYMR's next earnings report is estimated for 2026-11-03 — about 20 days away.
What is the analyst price target for KYMR?
The consensus analyst price target for KYMR is $138.20, about 29.5% above the current $106.68. Over the past 90 days, analysts recorded 1 upgrade, 8 maintains, and 0 downgrades.
How BestStocks tracks KYMR
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for KYMR, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 14, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
